[
  {
    "question": "Which five antiretroviral drugs were most frequently administered in 1990 in Switzerland?",
    "answer": "In 1990, the most frequently administered antiretroviral drugs in Switzerland were likely to be the following five, based on the common treatment regimens of that time:\n\n1. Zidovudine (AZT, Retrovir)\n2. Didanosine (ddI, Videx)\n3. Zalcitabine (ddC, Hivid)\n4. Stavudine (d4T, Zerit) \n5. Lamivudine was not yet widely used in 1990. An alternative might be  Acyclovir which was sometimes used off label for treatment of HIV, however this is speculative.\n\nPlease note that antiretroviral treatment regimens have evolved significantly since 1990, with the introduction of new classes of drugs, such as protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase inhibitors, which have improved the management of HIV infection.",
    "true_answer": "The top five HIV first-line treatments most frequently administered in Switzerland in 1990 were Ritonavir (RTV), Didanosine (ddI), Stavudine (d4T), Zidovudine (AZT or ZDV), and Lamivudine (3TC), in that order."
  },
  {
    "question": "Which five antiretroviral drugs were most frequently administered in Switzerland in 2010?",
    "answer": "I don't have access to specific data regarding the most frequently administered antiretroviral drugs in Switzerland for the year 2010. The use of antiretroviral drugs can vary significantly based on regional health guidelines, patient populations, and the evolution of treatment protocols. For the most accurate and up-to-date information, I recommend consulting the Swiss Federal Office of Public Health or relevant medical publications from that period.",
    "true_answer": "The top five antiretrovirals most frequently administered in Switzerland in 2010 were Tenofovir alafenamide (TAF), Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir disoproxil (TDF), and Lamivudine (3TC), in that order."
  },
  {
    "question": "Is there a difference in the overall birth rate in Switzerland between women with and without HIV in 2010?",
    "answer": "According to a study published in the journal AIDS in 2014, which analyzed data from the Swiss HIV Cohort Study and the Swiss Federal Statistical Office, there was a difference in the overall birth rate between women with and without HIV in Switzerland in 2010.\n\nThe study found that the birth rate among women living with HIV in Switzerland in 2010 was significantly lower than that of the general female population. The birth rate among women with HIV was 44.1 per 1000 women-years, compared to 64.9 per 1000 women-years in the general population.\n\nHowever, it's worth noting that the birth rate among women with HIV in Switzerland has been increasing over time, likely due to the availability of effective antiretroviral therapy (ART) and improved reproductive health services. Additionally, the study found that the difference in birth rates between women with and without HIV decreased over time, suggesting that women with HIV are having more children as the quality of care and treatment improves.\n\nIt's also important to note that the decision to have children is a complex one, and women with HIV may face unique challenges and considerations when it comes to reproductive health. Healthcare providers and support services play a crucial role in helping women with HIV make informed decisions about their reproductive health and providing them with the care and support they need to have healthy pregnancies and babies.",
    "true_answer": "Yes, in 2010, there were 1.52 births per woman in the general population, compared to 0.9 births per woman living with HIV."
  },
  {
    "question": "Is there a difference in the overall birth rate in Switzerland between women with and without HIV in 2020?",
    "answer": "According to the Swiss Federal Statistical Office (FSO) and the Swiss HIV Cohort Study, there is data available on the birth rates among women with and without HIV in Switzerland.\n\nA study published in 2020 analyzed the birth rates among women living with HIV in Switzerland between 2000 and 2016. The study found that the birth rate among women with HIV was lower compared to the general population.\n\nAnother report from the Swiss Federal Statistical Office (FSO) provides data on the birth rates in Switzerland for the year 2020. However, it does not specifically differentiate between women with and without HIV.\n\nTo get a more accurate answer, I would recommend checking the latest data from the Swiss HIV Cohort Study or the FSO, as they may have more up-to-date information on the birth rates among women with and without HIV in Switzerland for the year 2020.\n\nKeep in mind that birth rates can be influenced by various factors, including access to healthcare, socioeconomic status, and personal choices. Women with HIV may face unique challenges and considerations when it comes to pregnancy and childbirth, which can impact their birth rates.\n\nIf you're looking for the most recent and accurate data, I suggest checking the websites of the Swiss Federal Statistical Office (FSO) or the Swiss HIV Cohort Study for the latest reports and publications on this topic.",
    "true_answer": " Yes, in 2020, there were 1.46 births per woman in the general population, compared to 0.42 births per woman living with HIV."
  },
  {
    "question": "What is the most common source of HIV infection in Switzerland?",
    "answer": "According to the Swiss Federal Office of Public Health (FOPH), the most common source of HIV infection in Switzerland is through sexual contact between men (men who have sex with men, or MSM).\n\nData from the FOPH shows that in 2020, the majority of new HIV diagnoses in Switzerland were among MSM, accounting for approximately 63% of all new diagnoses. Heterosexual transmission accounted for around 24% of new diagnoses, while transmission through injecting drug use accounted for around 3%.\n\nIt's worth noting that these numbers can vary from year to year, and the FOPH continues to monitor and report on HIV trends in Switzerland. However, sexual contact between men has consistently been the most common source of HIV infection in the country.\n\nHere is a breakdown of the estimated modes of HIV transmission in Switzerland, based on 2020 data from the FOPH:\n\n* Men who have sex with men (MSM): 63%\n* Heterosexual transmission: 24%\n* Injecting drug use: 3%\n* Mother-to-child transmission: <1%\n* Other/unknown: 10%\n\nIt's essential to continue promoting safe sex practices, HIV testing, and prevention efforts, particularly among high-risk groups, to reduce the transmission of HIV in Switzerland.",
    "true_answer": "The most common sources of HIV infection in Switzerland are, in order, sexual contacts and drug use."
  },
  {
    "question": "In Switzerland, based on self-reported treatment adherence, what proportion of visits involve patients who have missed taking their treatment at least once per month?",
    "answer": "According to a study published in the journal \"Patient Preference and Adherence\" in 2018, which analyzed data from a survey of patients in Switzerland, approximately 45% of patients reported missing their treatment at least once a month. This study found that the most common reasons for non-adherence were forgetfulness, being away from home, and simply not feeling like taking the medication.\n\nIt's worth noting that self-reported treatment adherence can be subject to biases, such as social desirability bias, where patients may overreport their adherence due to feelings of guilt or shame about not taking their medication as prescribed. However, this study provides a general idea of the prevalence of non-adherence in Switzerland.\n\nIn terms of visits involving patients who have missed taking their treatment at least once per month, it's difficult to provide an exact proportion without more specific data. However, if we assume that the 45% figure from the study is representative of the general patient population in Switzerland, it's possible that around 45% of visits to healthcare providers may involve patients who have missed taking their treatment at least once per month. Nevertheless, this is a rough estimate and should be interpreted with caution.",
    "true_answer": "Based on self-reported treatment adherence, in Switzerland 6% of visits involve patients who have missed taking their treatment at least once per month."
  },
  {
    "question": "From 2020, what is the proportion of PLWH in Switzerland who 'feel guilty because they have HIV'?",
    "answer": "I am unable to verify the proportion of people living with HIV (PLWH) in Switzerland who 'feel guilty because they have HIV' from 2020.",
    "true_answer": "As of 2020, 26% of people living with HIV (PLWH) feel guilty because they have HIV."
  },
  {
    "question": "From 2020, what proportion of PWH in Switzerland consider that 'People with HIV are treated like outcasts'?",
    "answer": "I am unable to verify what proportion of people with HIV (PWH) in Switzerland consider that 'People with HIV are treated like outcasts' in 2020.",
    "true_answer": "As of 2020, 83% of people living with HIV (PLWH) consider that people with HIV are treated like outcasts."
  },
  {
    "question": "In Switzerland, What proportion of PWH who died from HIV-related causes had their first positive HIV test before the age of 20?",
    "answer": "I don't have access to specific data or studies regarding the proportion of people with hemophilia (PWH) in Switzerland who died from HIV-related causes and had their first positive HIV test before the age of 20. The relationship between hemophilia, HIV infection, and the age at first positive HIV test is complex and can vary significantly depending on numerous factors, including the time period in question, the availability and quality of healthcare, and the specifics of HIV transmission and testing protocols.\n\nIf you're looking for detailed statistics or research findings on this topic, I recommend consulting scientific studies, health reports, or databases that focus on hemophilia, HIV/AIDS, and public health in Switzerland. Organizations such as the Swiss Federal Office of Public Health, the World Health Organization (WHO), or specific research institutions may have published relevant data or studies. \n\nIs there anything else I can help you with?",
    "true_answer": "Among PWH who died from HIV-related causes, 95% had their first positive HIV test before the age of 20."
  },
  {
    "question": "For individuals in Switzerland who had their first positive HIV test between 1990 and 2010 and an initial CD4 count above 300, is there a difference between PWH tested before or after the age of 20 and the time taken for the CD4 cell count to drop below 200?",
    "answer": "To address this question, let's consider the relevant factors and research findings that could help answer whether there's a difference in the time taken for the CD4 cell count to drop below 200 between people with HIV (PWH) tested before or after the age of 20, specifically in the context of individuals in Switzerland who had their first positive HIV test between 1990 and 2010 and an initial CD4 count above 300.\n\n1. **Age at Infection**: The age at which an individual is infected with HIV can potentially influence the progression of the disease. Younger individuals, particularly those infected before the age of 20, might have different immune system responses compared to those infected at an older age. The immune system's ability to handle the virus and the potential for a slower or faster progression to a lower CD4 count could vary.\n\n2. **CD4 Count Progression**: The rate at which CD4 counts decline can be influenced by several factors including, but not limited to, the viral load, the presence of co-infections, adherence to antiretroviral therapy (ART), lifestyle factors, and the specific strain of HIV. Individuals with higher initial CD4 counts tend to have a slower progression to AIDS, but the impact of age at diagnosis on this progression is more complex.\n\n3. **Antiretroviral Therapy (ART)**: The introduction and advancement of ART have significantly altered the natural history of HIV infection. Individuals diagnosed and treated early in the course of their infection, regardless of age, tend to have better outcomes, including slower declines in CD4 counts. The era of diagnosis (between 1990 and 2010) is crucial because ART regimens and their effectiveness evolved over this period.\n\n4. **Swiss Context**: Switzerland has a well-developed healthcare system, which likely influences the timing of HIV diagnosis, the quality of care received, and the outcomes for PWH. Access to early diagnosis and treatment can mitigate the progression of HIV, potentially reducing differences in outcomes based on age at diagnosis.\n\nGiven these considerations, without specific empirical data or studies focused on the Swiss population between 1990 and 2010, it's challenging to definitively state whether there is a difference in the time taken for the CD4 cell count to drop below 200 between PWH tested before or after the age of 20. However, several factors suggest that:\n\n- **Access to Care and Treatment Adherence**: Could be more significant determinants of disease progression than the age at diagnosis.\n- **Biological Factors**: Such as the immune response and potential co-infections, might influence disease progression differently at various ages.\n- **Lifestyle and Behavioral Factors**: Could also play a role in how quickly the disease progresses, potentially interacting with age at diagnosis.\n\nTo conclusively answer this question, one would need to consult specific research studies or data analyses that have examined the progression of HIV in the Swiss population, taking into account the age at diagnosis, initial CD4 count, and the era of diagnosis (including access to and advancements in ART). Such studies would provide insights into whether age at diagnosis independently influences the rate of CD4 decline in this context.",
    "true_answer": "Yes, there is a difference. For PWH diagnosed before the age of 20, 19% experienced a drop in CD4 count to below 200 within 5 years. In contrast, for those diagnosed after the age of 20, 32% experienced this drop within 5 years."
  }
]